Latest Breaking News On - Dalibor sames - Page 1 : comparemela.com
Gilgamesh Pharmaceuticals, a biotechnology company that uses psychedelic-related drugs to treat neuropsychiatric disorders, reported Thursday it has raised $27 million in a Series A funding round led by Prime Movers Lab.
Other investors involved in the round included the Noetic Psychedelic Fund LP, Gron Ventures, Route 66 Ventures, JLS Fund and Palo Santo Investors.
Prime Movers Lab, a partnership that invests in breakthrough scientific startups, is known for raising funds for inventors in energy, transportation, infrastructure, manufacturing, human augmentation, and agriculture.
With the newly raised capital, New York-based Gilgamesh plans to add more members to its team, including a COO, head of R&D and CBO. It will also work on advancing its programs toward clinical candidate selection and broadening its IP portfolio.
Amy-kruse
Jonathan-sporn
Jeff-witkin
Mike-cunningham
Andrew-kruegel
Noetic-psychedelic-fund
Movers-lab
Gilgamesh-pharmaceuticals
Prime-movers
Gron-ventures
Palo-santo
New-york-based-gilgamesh